Yanqiu Liu is a china associate in the Corporate practice of Paul Hastings.
His practice concentrates on initial public offerings, regulatory compliance and other corporate matters. Mr. Liu also has experience in dispute resolution and compliance investigation.
Mr. Liu passed the bar in China in 2016, but does not hold a current practicing certificate. Mr. Liu is admitted to the New York State Bar. He is fluent in English and Mandarin.
UCLA School of Law, LL.M., 2018
East China University of Political Science and Law, LL.B., 2017
Represented SinoMab BioScience Limited in its US$176.5 million global offering and IPO on the Hong Kong Stock Exchange as a Chapter 18A biotech company.
Represented Fosun Tourism Group in its US$428 million global offering and IPO on the Hong Kong Stock Exchange.
Represented aUS-based multinational finance and insurance corporation in its sale of equity interest in a PRC joint venture to a large Chinese conglomerate.
Represented one of the largest integrated shipping companies in China on CFIUS-related matters with respect to its substantial acquisition.
Represented aPRC-based private equity fund in HKIAC arbitration in disputes arising from acquisition of a PRC subsidiary from a US-listed company.
Represented a US-based private equity fund in HKIAC arbitration in disputes arising from real estate joint ventures in China and coordinated strategy for parallel proceedings in CIETAC.
Represented various HK listed companies including Fosun Tourism Group, Phoenix Media, Phoenix New Media and Dalian Port (PDA) Company Limited on Hong Kong legal and regulatory compliance matters.
Represented several global biopharmaceutical companies in conducting numerous internal investigations regarding their business operations in China involving improper payments, off-label promotion, embezzlement, and books and records violations.